Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioPharma CreditLSE:BPCR -0.81%51 3-Year Share Buyback Ratio is 5.10 as of Dec. 2025, which is 229% above its 10-year median of 1.55. GuruFocus rates LSE:BPCR with a GF Score™ of 51/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,141 Asset Management companies, BioPharma Credit ranks better than 89.13% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. BioPharma Credit's current 3-Year Share Buyback Ratio was 5.10%.
The historical rank and industry rank for BioPharma Credit's 3-Year Share Buyback Ratio or its related term are showing as below:
LSE:BPCR'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -14.5 Med: 1.55 Max: 5.1
Current: 5.1
During the past 9 years, BioPharma Credit's highest 3-Year Share Buyback Ratio was 5.10%. The lowest was -14.50%. And the median was 1.55%.
LSE:BPCR's 3-Year Share Buyback Ratio is ranked better than 89.13% of 1141
companies
in the Asset Management industry
Industry Median: -0.8
vs LSE:BPCR: 5.10
BioPharma Credit (LSE:BPCR) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
BioPharma Credit 3-Year Share Buyback Ratio Related Terms
LSE:BPCR vs BLK, BX, KKR: 3-Year Share Buyback Ratio Comparison
For the Asset Management subindustry, BioPharma Credit's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit 3-Year Share Buyback Ratio vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's 3-Year Share Buyback Ratio falls into.
BioPharma Credit 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of 5.10 mean?
BioPharma Credit (LSE:BPCR) has a 3-Year Share Buyback Ratio of 5.10 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for BioPharma Credit and its competitors. This is 229% above median its historical median of 1.55. According to the industry distribution chart, BioPharma Credit ranks #124 out of 1141 companies in the Asset Management industry, placing it in the top 10.9%.
Is BioPharma Credit's 3-Year Share Buyback Ratio too high?
BioPharma Credit's current 3-Year Share Buyback Ratio of 5.10 is 229% above median its 10-year median of 1.55. Based on the distribution chart, BioPharma Credit ranks #124 out of 1141 companies in the Asset Management industry, which is in the top quartile — a strong position relative to peers. Overall, BioPharma Credit has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's 3-Year Share Buyback Ratio compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #124 out of 1141 companies for 3-Year Share Buyback Ratio. This places BioPharma Credit in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for an Asset Management company?
A good 3-Year Share Buyback Ratio depends on the Asset Management industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for BioPharma Credit and its competitors. BioPharma Credit's current 3-Year Share Buyback Ratio is 5.10, which is 229% above median its own 10-year median of 1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.97 — trading 1.5% above its estimated fair value. The current 3-Year Share Buyback Ratio is 5.10, which is 229% above median its 10-year median of 1.55. BioPharma Credit's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current 3-Year Share Buyback Ratio is 5.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued.
The current stock price of $0.97 is trading 1.5% above its estimated GF Value™ of $0.96.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
3-Year Share Buyback Ratio: 5.10 (229% above median its 10-year median of 1.55)
GF Value™: $0.96 vs. price of $0.97 (1.5% above fair value)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
51GF Score
Get the complete analysis for LSE:BPCR
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
